Harnessing Cadherin-17 for Advanced Solid Tumors
At Arbele, we are revolutionizing gastrointestinal cancers and solid tumors treatment through our groundbreaking Cadherin-17 biomarker technology. Our proprietary CDH17 biomarker transforms the landscape of cancer therapeutics, offering precision and effectiveness in targeting gastrointestinal cancers. Committed to advancing medical science, we leverage CDH17 to develop targeted therapies that improve patient outcomes and quality of life. Join us on our mission to provide cutting-edge solutions, bringing hope and healing to those affected by gastrointestinal and other advanced solid cancers.
Targeting Cancer with Innovative Immunotherapy
Our cutting-edge innovative immunotherapy targets cancer cells with unprecedented accuracy, minimizing side effects and maximizing efficacy. By focusing on CDH17, we develop advanced treatments that hold promise for addressing the significant unmet medical needs in advanced solid tumors.
Our Suite of Therapeutics
Tri-Ax/Bispecific antibody platform
Unlock the power of versatility of multi-specific antibody.
Antibody Drug Conjugate (ADC)
Innovative precision for targeted destruction.
Advanced Cell Therapy (CAR)
Experience the future of cancer treatment with cutting-edge solutions.
Recent Recognitions and Achievements
- AFCR BRACE award winner 2020
- ASCO Breakthrough — Top Abstract
- 2019 (ARB202)
- 2023 (ARB202)
- Greater Bay Area SME Innovation and Entrepreneurship Competition cum 2023 Guangdong Maker Competition Guangzhou Division – 2nd prize
- Hong Kong, Macao and Taiwan Innovation and Entrepreneurship Competition 2022 – 2nd prize
- 2022 年中国创新创业大赛荣获 全国“优秀企业奖”
- 3rd Asia Exhibition of Innovations and Inventions Hong Kong – Gold medal (https://www.inventions-asia.hk/)
Follow Arbele’s Progress
Sign up to receive new information and updates from us.